Sana’s 14‑Month Win
Sana Biotechnology reported continued positive clinical results through 14 months from its islet cell transplantation study — notably without immunosuppression — reinforcing its platform approach to cell therapy R&D announced. Morgan Stanley reiterated coverage on the strength of those diabetes data, underscoring investor interest in data-driven platform models reported.
The investigator‑sponsored, first‑in‑human transplant at Uppsala University Hospital used UP421 — an allogeneic primary islet product modified with Sana’s hypoimmune (HIP) platform — and showed circulating C‑peptide at 14 months with a meal‑responsive increase on mixed meal tolerance testing, indicating sustained transplanted beta‑cell functionfinance.yahoo.com. Investigators reported no immunosuppression was administered and no safety signals through month‑14, but the disclosure notes the dataset reflects a single, low‑dose patient and the trial was not intended to establish efficacybiospace.com. Morgan Stanley reiterated coverage, calling the durability of the observed immune evasion a “meaningful platform‑level de‑risking” and maintaining an Overweight stance while noting Sana was trading near $3.28 with an ~$875M market cap and had declined ~24% year‑to‑date before the announcementinvesting.com. Sana said it plans to advance a HIP‑modified, stem‑cell‑derived candidate SC451 toward an IND filing and a Phase‑1 start as early as 2026, and the company presented the full 14‑month dataset at the ATTD conference to support that regulatory pathgurufocus.com.
